Literature DB >> 36033135

Update on Axial Spondyloarthritis.

Anne E Winkler1, Micah Miller2.   

Abstract

Understanding of the spondyloarthritis diseases has changed significantly in the last 15 years. It is now clear that there are patients with and without radiographic changes and the terminology has changed to reflect that: radiographic axial spondyloarthritis and non-radiographic axial spondyloarthritis. In addition, the importance of the presence of inflammatory back pain with spondyloarthritis in making the diagnosis is now well established. It is also clear that women are much more likely to develop axial spondyloarthritis than previously thought. Finally, there are treatments now available to treat axial spondyloarthritis and more hopefully to be approved in the next year. Copyright 2022 by the Missouri State Medical Association.

Entities:  

Mesh:

Year:  2022        PMID: 36033135      PMCID: PMC9312440     

Source DB:  PubMed          Journal:  Mo Med        ISSN: 0026-6620


  19 in total

Review 1.  Ankylosing Spondylitis and Axial Spondyloarthritis.

Authors:  Joel D Taurog; Avneesh Chhabra; Robert A Colbert
Journal:  N Engl J Med       Date:  2016-06-30       Impact factor: 91.245

2.  Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Authors:  Chenglong Han; Don W Robinson; Monica V Hackett; L Clark Paramore; Kathy H Fraeman; Mohan V Bala
Journal:  J Rheumatol       Date:  2006-09-01       Impact factor: 4.666

Review 3.  Genetics of spondyloarthritis--beyond the MHC.

Authors:  John D Reveille
Journal:  Nat Rev Rheumatol       Date:  2012-04-10       Impact factor: 20.543

Review 4.  Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment.

Authors:  Philip J Mease
Journal:  Curr Opin Rheumatol       Date:  2017-07       Impact factor: 5.006

5.  How to diagnose axial spondyloarthritis early.

Authors:  M Rudwaleit; D van der Heijde; M A Khan; J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

6.  Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.

Authors:  Charles G Helmick; David T Felson; Reva C Lawrence; Sherine Gabriel; Rosemarie Hirsch; C Kent Kwoh; Matthew H Liang; Hilal Maradit Kremers; Maureen D Mayes; Peter A Merkel; Stanley R Pillemer; John D Reveille; John H Stone
Journal:  Arthritis Rheum       Date:  2008-01

7.  Gender differences in ankylosing spondylitis-associated cumulative healthcare utilization: a population-based cohort study.

Authors:  Hsin-Hua Chen; Tzeng-Ji Chen; Yi-Ming Chen; Chiu Ying-Ming; Der-Yuan Chen
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

8.  2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.

Authors:  Michael M Ward; Atul Deodhar; Lianne S Gensler; Maureen Dubreuil; David Yu; Muhammad Asim Khan; Nigil Haroon; David Borenstein; Runsheng Wang; Ann Biehl; Meika A Fang; Grant Louie; Vikas Majithia; Bernard Ng; Rosemary Bigham; Michael Pianin; Amit Aakash Shah; Nancy Sullivan; Marat Turgunbaev; Jeff Oristaglio; Amy Turner; Walter P Maksymowych; Liron Caplan
Journal:  Arthritis Rheumatol       Date:  2019-08-22       Impact factor: 15.483

Review 9.  Role of HLA-B27 in the pathogenesis of ankylosing spondylitis (Review).

Authors:  Bin Chen; Jia Li; Chongru He; Dahe Li; Wenwen Tong; Yuming Zou; Weidong Xu
Journal:  Mol Med Rep       Date:  2017-02-24       Impact factor: 2.952

10.  Characterization of Patients With Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis in the US-Based Corrona Registry.

Authors:  Philip J Mease; Désirée Van Der Heijde; Chitra Karki; Jacqueline B Palmer; Mei Liu; Renganayaki Pandurengan; Yujin Park; Jeffrey D Greenberg
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-10-08       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.